Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Mol Cancer Ther (2016) 15 (4): 628–639.

https://doi.org/10.1158/1535-7163.MCT-15-0758

Published: 05 April 2016

View article titled, Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Includes: Supplementary data

Journal Articles

Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation

Mol Cancer Ther (2015) 14 (12_Supplement_2): A149.

https://doi.org/10.1158/1535-7163.TARG-15-A149

Published: 01 December 2015

View article titled, Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation

Journal Articles

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

Mol Cancer Ther (2012) 11 (4): 1006–1016.

https://doi.org/10.1158/1535-7163.MCT-11-0765

Published: 08 April 2012

View article titled, NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

Includes: Supplementary data

Journal Articles

Abstract B230: NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations.

Marina Ciomei, Ivan Fraietta, Sabrina Cribioli, Aurelio Marsiglio, Daniele Casero, Marcella Nesi, Daniele Donati, Antonella Isacchi, Enrico Pesenti, Arturo Galvani, Andrea Lombardi Borgia

Mol Cancer Ther (2011) 10 (11_Supplement): B230.

https://doi.org/10.1158/1535-7163.TARG-11-B230

Published: 12 November 2011

View article titled, Abstract B230: NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations.

Journal Articles

Abstract B241: Targeting the mitotic checkpoint with NMS-P153, a novel MPS1 kinase inhibitor.

Riccardo Colombo, Marina Caldarelli, Maria Laura Giorgini, Francesco Sola, Paolo Cappella, Claudia Perrera, Nilla Avanzi, Jay A. Berthrand, Enrico Pesenti, Antonella Isacchi, Daniele Donati, Jurgen Moll, Arturo Galvani

Mol Cancer Ther (2011) 10 (11_Supplement): B241.

https://doi.org/10.1158/1535-7163.TARG-11-B241

Published: 12 November 2011

View article titled, Abstract B241: Targeting the mitotic checkpoint with NMS-P153, a novel MPS1 kinase inhibitor.

Journal Articles

Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.

Elena Ardini, Maria Menichincheri, Patrizia Banfi, Maria Beatrice Saccardo, Luisa Rusconi, Nilla Avanzi, Nadia Amboldi, Daniele Casero, Sabrina Cribioli, Antonella Isacchi, Daniele Donati, Enrico Pesenti, Arturo Galvani

Mol Cancer Ther (2011) 10 (11_Supplement): A232.

https://doi.org/10.1158/1535-7163.TARG-11-A232

Published: 12 November 2011

View article titled, Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.

Journal Articles

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

Clara Albanese, Rachele Alzani, Nadia Amboldi, Nilla Avanzi, Dario Ballinari, Maria Gabriella Brasca, Claudio Festuccia, Francesco Fiorentini, Giuseppe Locatelli, Wilma Pastori, Veronica Patton, Fulvia Roletto, Francesco Colotta, Arturo Galvani, Antonella Isacchi, Jurgen Moll, Enrico Pesenti, Ciro Mercurio, Marina Ciomei

Mol Cancer Ther (2010) 9 (8): 2243–2254.

https://doi.org/10.1158/1535-7163.MCT-10-0190

Published: 09 August 2010

View article titled, Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

Includes: Supplementary data

Journal Articles

Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study

Giuseppe Locatelli, Roberta Bosotti, Marina Ciomei, Maria G. Brasca, Raffaele Calogero, Ciro Mercurio, Francesco Fiorentini, Matteo Bertolotti, Emanuela Scacheri, Angela Scaburri, Arturo Galvani, Enrico Pesenti, Thierry De Baere, Jean-Charles Soria, Vladimir Lazar, Antonella Isacchi

Mol Cancer Ther (2010) 9 (5): 1265–1273.

https://doi.org/10.1158/1535-7163.MCT-09-1163

Published: 09 May 2010

View article titled, Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study

Includes: Supplementary data

Journal Articles

Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-Ras^G12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging

Anna Degrassi, Micaela Russo, Cristina Nanni, Veronica Patton, Rachele Alzani, Anna M. Giusti, Stefano Fanti, Marina Ciomei, Enrico Pesenti, Gemma Texido

Mol Cancer Ther (2010) 9 (3): 673–681.

https://doi.org/10.1158/1535-7163.MCT-09-0726

Published: 09 March 2010

View article titled, Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-RasG12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging

Journal Articles

Abstract C202: Targeting the mitotic checkpoint for cancer therapy with NMS‐P715, a novel MPS1 kinase inhibitor

Riccardo Colombo, Marina Caldarelli, Milena Mennecozzi, Maria L. Giorgini, Francesco Sola, Paolo Cappella, Dario Ballinari, Claudia Perrera, Stefania Re Depaolini, Luisa Rusconi, Nilla Avanzi, Daniele Volpi, Roberto Bossi, Jay A. Bertrand, Enrico Pesenti, Antonella Isacchi, Daniele Donati, Jurgen Moll

Mol Cancer Ther (2009) 8 (12_Supplement): C202.

https://doi.org/10.1158/1535-7163.TARG-09-C202

Published: 10 December 2009

View article titled, Abstract C202: Targeting the mitotic checkpoint for cancer therapy with NMS‐P715, a novel MPS1 kinase inhibitor

Journal Articles

Abstract PR-3: Antitumor efficacy on glioma models of the dual CDK/TRKA inhibitor PHA‐848125, able to cross the blood brain barrier

Clara Albanese, Wilma Pastori, Giuseppe Locatelli, Rachele Alzani, Francesco Fiorentini, Claudio Festuccia, Enrico Pesenti, Arturo Galvani, Antonella Isacchi, Ciro Mercurio, Maria Gabriella Brasca, Marina Ciomei

Mol Cancer Ther (2009) 8 (12_Supplement): PR-3.

https://doi.org/10.1158/1535-7163.TARG-09-PR-3

Published: 10 December 2009

View article titled, Abstract PR-3: Antitumor efficacy on glioma models of the dual CDK/TRKA inhibitor PHA‐848125, able to cross the blood brain barrier

Journal Articles

Abstract A213: Potent anticancer activity in vitro and in vivo by NMS‐E973, a novel synthetic inhibitor of HSP90

Mol Cancer Ther (2009) 8 (12_Supplement): A213.

https://doi.org/10.1158/1535-7163.TARG-09-A213

Published: 10 December 2009

View article titled, Abstract A213: Potent anticancer activity in vitro and in vivo by NMS‐E973, a novel synthetic inhibitor of HSP90

Journal Articles

Abstract A243: Characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models

Elena Ardini, Maria Menichincheri, Cristina De Ponti, Nadia Amboldi, Maria Beatrice Saccardo, Gemma Texido, Micaela Russo, Paolo Orsini, Tiziano Bandiera, Andrea Lombardi Borgia, Antonella Isacchi, Enrico Pesenti, Francesco Colotta, Paola Magnaghi,, Arturo Galvani, Nerviano Medical

Mol Cancer Ther (2009) 8 (12_Supplement): A244.

https://doi.org/10.1158/1535-7163.TARG-09-A244

Published: 10 December 2009

View article titled, Abstract A243: Characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models

Journal Articles

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Mol Cancer Ther (2007) 6 (12): 3158–3168.

https://doi.org/10.1158/1535-7163.MCT-07-0444

Published: 18 December 2007

View article titled, PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Includes: Supplementary data

Journal Articles

Nemorubicin synergizes with agents currently used for the treatment of hepatocellular carcinoma (HCC)

Cristina Geroni, Dario Ballinari, Aurelio Marsiglio, Enrico Pesenti, Valter Croci, Luigi Quintieri

Mol Cancer Ther (2007) 6 (11_Supplement): A277.

Published: 01 November 2007

View article titled, Nemorubicin synergizes with agents currently used for the treatment of hepatocellular carcinoma (HCC)

Journal Articles

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Tinya J. Abrams, Lesley J. Murray, Enrico Pesenti, Vicky Walker Holway, Tina Colombo, Leslie B. Lee, Julie M. Cherrington, Nancy K. Pryer

Mol Cancer Ther (2003) 2 (10): 1011–1021.

Published: 24 October 2003

View article titled, Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Journal Articles

Camptothecin Poly[N-(2-Hydroxypropyl) Methacrylamide] Copolymers in Antitopoisomerase-I Tumor Therapy: Intratumor Release and Antitumor Efficacy

Moreno Zamai, Martin vandeVen, Mariella Farao, Enrico Gratton, Alberto Ghiglieri, Maria G. Castelli, Erminia Fontana, Roland d’Argy, Antonio Fiorino, Enrico Pesenti, Antonino Suarato, Valeria R. Caiolfa

Mol Cancer Ther (2003) 2 (1): 29–40.

Published: 01 January 2003

View article titled, Camptothecin Poly[N-(2-Hydroxypropyl) Methacrylamide] Copolymers in Antitopoisomerase-I Tumor Therapy: Intratumor Release and Antitumor Efficacy

NARROW

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

Abstract B230: NMS-P948, a potent dual FLT3/KIT inhibitor, also active on secondary resistance mutations.

Abstract B241: Targeting the mitotic checkpoint with NMS-P153, a novel MPS1 kinase inhibitor.

Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.

Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy

Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study

Efficacy of PHA-848125, a Cyclin-Dependent Kinase Inhibitor, on the K-Ras^G12DLA2 Lung Adenocarcinoma Transgenic Mouse Model: Evaluation by Multimodality Imaging

Abstract C202: Targeting the mitotic checkpoint for cancer therapy with NMS‐P715, a novel MPS1 kinase inhibitor

Abstract PR-3: Antitumor efficacy on glioma models of the dual CDK/TRKA inhibitor PHA‐848125, able to cross the blood brain barrier

Abstract A213: Potent anticancer activity in vitro and in vivo by NMS‐E973, a novel synthetic inhibitor of HSP90

Abstract A243: Characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Nemorubicin synergizes with agents currently used for the treatment of hepatocellular carcinoma (HCC)

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Camptothecin Poly[N-(2-Hydroxypropyl) Methacrylamide] Copolymers in Antitopoisomerase-I Tumor Therapy: Intratumor Release and Antitumor Efficacy

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only